Italian Authorities Seize Over $1B Worth of Amphetamines Originating From Syria
Italian Authorities Seize Over $1B Worth of Amphetamines Originating From Syria
23 September August 2020: Italian Authorities Seize Over $1B Worth of Amphetamines Originating From Syria
Italian police intercepted and seized 14 tons of amphetamines with a street value of approximately $1.15 billion at the Italian port of Salerno in early July. This huge shipment was suspected to have originated from Syria before being transported to the base of a notorious European crime organisation in Naples.
‘Largest seizure of amphetamines in the world’
In video footage the Italian Financial Guard military force posted to their Twitter account, authorities can be seen using electric saws to cut through 6-foot-high cylinders in shipping containers. The Customs Police Col. Domenico Napolitano called the discovery the largest seizure of amphetamines in the world after finding over 85 million pills inside the cylinders.
Syria Identified as One of the Largest Producers of Amphetamines in the World
Syria has become one of the world’s largest producers of amphetamines in recent years, and with production and distribution of such drugs in Europe appearing to have slowed down during the pandemic, the same cannot be said for Syria. As such, authorities are suspecting that crime organisations are placing orders and smuggling drugs from Syria into Europe.
Randox Toxicology
Randox Toxicology are helping to fight drug trafficking by continually investing in new technologies to aid in the rapid and large-scale screening for drugs of abuse. We are world leaders in drug testing solutions with the capability of detecting over 500 drug and drug metabolites using our innovative Biochip Array Technology – the most comprehensive on the drug testing market. Our patented Biochip Array Technology works across a variety of matrices including whole blood, urine and oral fluid.
Using our revolutionary Biochip Array Technology, the Evidence MultiSTAT is a fully automated benchtop analyser that enables onsite, simultaneous testing for up to 21 classical, synthetic or prescription drugs from a single sample in under 20 minutes. This quick and highly reliable technology makes it perfect for use in non-laboratory settings for people with no lab experience.
To find out more about our Biochip Array Technology and our Evidence Series range of analysers, visit www.randoxtoxicology.com or email info@randoxtoxicology.com
Randox Toxicology Products and Services
BIOCHIP
EVIDENCE
ELISA
MATRICES
Want to know more about Randox?
Contact us or visit our homepage to view more.
Alzheimerās Disease Month at Randox Biosciences
15 September 2020
Alzheimer’s Risk Array from Randox Biosciences
September 2020 marks the 9th World Alzheimer’s Month
World Alzheimer’s Month is the international campaign every September to raise awareness and challenge the stigma that surrounds dementia. Alzheimer’s Disease is a progressive neurodegenerative disease associated with cognitive decline and is the most common form of dementia. It is defined as an irreversible, progressive brain disorder in which parts of the brain are damaged over time.
According to Alzheimer’s Disease International dementia affects people differently – no two people will experience symptoms in exactly the same way. A person’s personality, general health and social situation are all important factors in determining the impact of dementia on an individual. The most common signs are memory loss, the loss of practical abilities, problems with language, changes in mood and behaviour, and withdrawal from work or social activities.1
Who is affected?
- There are currently around 850,000 people with dementia in the UK. This is projected to rise to 1.6 million by 2040.2
- 209,600 will develop dementia this year, that’s one every three minutes.2
- 1 in 6 people over the age of 80 have dementia.2
- 70% of people in care homes have dementia or severe memory problems.2
- There are over 42,000 people under 65 with dementia in the UK.2
The Randox Alzheimer’s Risk Array is a rapid and highly sensitive blood test facilitating direct Apo E genotyping without the need for molecular testing. Apo E is present in three common isoforms; Apo E2, Apo E3 and Apo E4. Alzheimer’s Disease risk is increased in individuals with the Apo E4 allele.
Apolipoprotein E (ApoE) is a major cholesterol carrier that supports lipid transport and injury repair in the brain. ApoE polymorphic alleles are the main genetic determinants of Alzheimer Disease risk. Presence of ApoE4 allele is associated with increased risk for cerebral amyloid angiopathy and age-related cognitive decline during normal ageing.3
Apo E4 is one of three common isoforms of Apo E and is recognised as a major genetic risk factor the development of Alzheimer’s disease. Apo E4 triggers inflammatory cascades that cause neurovascular dysfunction, including blood-brain barrier breakdown, leakage of blood-derived toxic proteins into the brain and reduction in the length of small vessels.
Utilising revolutionary patented Biochip Technology, the Randox Alzheimer’s Risk Array provides a unique solution for the measurement of both total apoE and the apo E4 isoform levels from a single patient sample, facilitating the fast and accurate classification of Alzheimer’s disease risk in comparison to brain scanning (CT and MRI).
Key Benefits of Alzheimer’s Risk Array
- 2-plex testing from a single sample
- Assist in research and development of potential treatment
- Early risk detection of disease
- Small sample volume
- Fast throughput
Biochip Technology
Biochip Technology is an immunoassay testing platform and is the core of Randox Biosciences. The intelligent chemically activated 9x9mm ceramic biochip acts as a solid phase reaction vessel. Benefits of Biochip Technology include:
- The biochips are pre-fabricated with discrete test regions (DTR’s)
- Highly accurate testing
- Better diagnosis
- Reduced sample volume
- Wide test menu
- Multiple sample types can be used on a Biochip
- Cost consolidation
Evidence Investigator
The Evidence Investigator offers a high throughput even as a compact, semi-automated analyser promoting lab efficiency and cost saving solutions. Utilising Randox’s patented Biochip Technology, this platform facilitates multiplex testing in a rapid, accurate and easy-to-use format providing a comprehensive patient profile from one single sample. This analyser is suitable for medium throughput laboratories and is extremely robust with only one moving part.
For further information on our early risk detection testing for Alzheimer’s Disease, please email info@randoxbiosciences.com
References
- https://www.alz.co.uk/info/early-symptoms
- https://www.alzheimers.org.uk/about-us/news-and-media/facts-media
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898682/
RESEARCH
BIOPHARMA
CLINICAL LAB
BIOREAGENTS
Preparing Your Vineyard for Harvest: A Randox Food Diagnostics Blog
28 August 2020
Preparing your vineyard for harvest: Excellence in every glass
Each year from August through October and maybe a little later, the Northern Hemisphere comes alive with the excitement and rush of harvest as wine makers celebrate with festivals, dinners and get together as the yearlong grape growing season comes to an end and harvest begins.
Producing the highest quality wine grapes is dependent upon many factors – mainly the right amount of sun and rain. The growing process can be stressful for winemakers as they anxiously keep a close eye on weather conditions, in hope that it’s clear of frosts, heatwaves and hail. These can all have detrimental impacts on the vineyard.
However, this year it hasn’t been weather conditions that have been a worry for winemakers. Instead, many vineyards have been significantly impacted by the ongoing COVID-19 pandemic and events that once brought life to local communities and vineyards are now taking place online. Channels for selling wine such as hotels, restaurants and airports have dried up with current restrictions, and online and supermarket sales have never been more important.
Like many industries the food and beverage sector has continued to operate through one of the most challenging times. Using a combination of expert knowledge and technology has ensured that the expectation put upon winemakers to create excellent wine is regularly achieved even in the toughest conditions.
Did you know that a wide range of elements are measured to ensure perfection in every bottle, including levels of acidity and sugar ripeness relevant to the desired style of wine? Technology has been giving winemakers a helping hand in ensuring the quality of each harvest for many years including Randox Food‘s RX misano – a compact, fast and efficient benchtop spectrophotometer capable of gaining results in 8-15 minutes.
For more information please visit Randox Food Diagnostics or email: info@randoxfooddiagnostics.com
Want to know more?
Contact us or visit our Randox Food Diagnostics website.
Related Products
Meat & Seafood
Milk
Honey
Wine
Rise in Lockdown Drug Use Linked to Mental Health Issues
19 August 2020: Rise in Lockdown Drug Use Linked to Mental Health Issues
A new survey has been published reporting on the devastating effects that nationwide and global lockdowns have had on people suffering with mental health issues and substance abuse.
The survey delves into not only what drugs are being taken, but also crucially, why people are resorting to substance abuse during lockdown. Benzodiazepines and cannabis reportedly ‘greatly increased’ or ‘increased’ in use within the first 4 weeks of the pandemic. Approximately one in two people surveyed are taking drugs currently; a sharp increase from one in five people before the pandemic.
Anxiety, loneliness and stress
The majority of respondents (71%) reported that they are still using drugs for fun, however there was also a significant rise in those reporting their reason for drug use as a way to cope with their mental health.
Mental health concerns that came up were; anxiety, loneliness, stress and escaping reality. Previously when this survey was conducted before the pandemic, each of these elements of mental health were reported at around 20%. Now however, they are being reported in approximately 30-50% of respondents.
This is understandable, given the uncertainty of what lies ahead, and the fact that some will also be struggling with unemployment, money, relationships and self-confidence.
Reduced Health Care Options
Unfortunately, many health facilities have been operating at reduced capacity and have been unable to see patients due to the outbreak, meaning that people are indeed turning to drug use instead of professional medical help.
As countries begin to open back up again and resume more normal health care activities, they will almost certainly see a rise in people seeking treatment for drug use.
Using our revolutionary Biochip Array Technology, the Evidence MultiSTAT is a fully automated benchtop analyser that enables onsite, simultaneous testing for up to 21 classical, synthetic or prescription drugs from a single sample in under 20 minutes.
To find out more about our Biochip Array Technology and our Evidence Series range of analysers, please visit randoxtoxicology.com or email info@randoxtoxicology.com
Randox Toxicology Products and Services
BIOCHIP
EVIDENCE
ELISA
MATRICES
Want to know more about Randox?
Contact us or visit our homepage to view more.
Dr Peter FitzGerald: “Nothing will ever be the same again.”
Dr Peter FitzGerald: Nothing will ever be the same again.
An Interview with Ulster Business Editor John Mulgrew in The Belfast Telegraph, in which Dr FitzGerald speaks to John about developing and helping roll out millions of tests for Covid-19, a forever changed society, the high likelihood of a similar pandemic returning and when a vaccine for the virus could be found.
Dr Peter FitzGerald’s expertise and opinion has probably never been taken as seriously as it has in the last few months.
“Nothing will be the same again,” he tells Ulster Business. And, of course, he’s right.
His firm Randox – based in Antrim – has been on the front line of testing for Covid-19 right across the UK and beyond. And as a result, he’s hired hundreds of new staff and built a £30m testing lab to deal with additional deluge of work resulting from a global pandemic unlike anyone here has ever seen.
“I think there is a reasonable chance there will be more pandemics, with globalisation and increased population,” he told Ulster Business. “I have no idea how much it will come back again in second wave.
“We know we have the capacity as a company to respond, and respond well. I suspect the country is going to be better prepared… it’s hard to predict.”
The medical testing giant’s first involvement with the current coronavirus strain began back in January, before it became an increasingly concerning dinner conversation in homes across Northern Ireland.
“In late January, research called and were looking at doing a test,” Peter said. “We downloaded the genetic sequence of the virus and spent the next two weeks developing a test. We can do it very quickly, as we already had coronaviruses on chip.
“It was sent to Public Health England, which took a while to prove it. We then got a contract to test for the NHS… we were doing what we thought was for the national good.”
The initial deal didn’t include all of the UK, but Randox is now also testing Northern Ireland.
“We do the testing and we have different analysers that do the testing as well, which we sell to labs across the world.”
The virus has led to a new complete lab being built (in which Peter is pictured in) to deal with the additional testing. “We decided to accelerate the manufacturing in our Randox Science Park in Antrim,” he says.
As a result, it has hired around 200 staff in the space of six to eight weeks to deal with the surge.
“Because we had closely related strains of the virus, it was wasn’t so difficult to modify our tests to allow for slightly different variations… once we got the contract we soon realised that we didn’t have enough lab space to deal with the ramp up.
“We then decided to be 33,000 sq ft of new lab space, and it was needed in three weeks. We got that done – work was 24 hours a day, and seven days a week. It’s now operating well. That has been very important in the process.”
Randox had a workforce of around 1,450 worldwide before the coronavirus crisis began, but has since taken on around 280 additional staff for a range of roles, partly in ramping up demand for the additional testing.
“A lot were being taken on a temporary basis but many will be permanent. We are not sure of the final numbers, but well over 100.” Those roles include scientists, manufacturers, and engineers.
“Nothing will be the same again,” Peter says. “What it has done is heightened the importance of testing. People sometimes don’t know what we do here at Randox… but people now realise.
“In the end, it’s a good thing. We are advocates of testing. It identities disease before symptoms occur and can save lives in many occasions. It saves lives and saves costs. It fits in with what we have been trying to do for years… as far as we are concerned, it’s the silver lining.
“We have customers worldwide and other products kept going. We moved around 100 scientists into Covid-related things and then they have gone back to normal jobs as we bring in new people.
“Some of our R&D projects have changed, new systems and new analysers allow for efficient and accurate testing.”
Peter says that just a small element of the business has seen a decrease amid the crisis, while other areas around Covid-19 have grown. “Only a small element of core business decreased. But our Covid and other genetic products have increased… overall sales will be up and by end of year normal business up as well.”
As a result of the latest expansion and growth across the business, generally speaking, Peter says the workforce looks set to climb to 1,650, with around 500-600 based at its main headquarters, just outside Antrim.
Peter’s also keen to reiterate the importance of Northern Ireland and its people to Randox. “This is our home base. It’s where we do our primary R&D and manufacturing. We also have a facility in Donegal.”
And, could all of this happen again soon, with a further outbreak or a similarly devastating strain or pandemic?
“(We are) more prepared and our technology is getting more accepted through bio chips. Early detection is a very important next stage. You don’t want people who have a cough or fever to think they have Covid all the time. That is where testing comes in and that differentiates.”
Peter says the next stop forward in a bid to address similar future incidents it also understanding how our immune systems work – better.
“The other major step forward in many ways is understanding the immune system better. How to better respond to infection. This will be very important.
“Some people are susceptible, and this could be genetic. (It’s about) working on certain genes in those who may have a bad attack. It will prepare humans better, the body’s defence, dealing with it as well.
“I have a deficiency in a particular gene which means I’m more susceptible to respiratory (conditions) but the spin-off of the gene means I’m less susceptible to certain cancers. This is the issue – it is so complex. One could be a strength and one moment, a weakness.”
And as for the formulation of a proven vaccine, Peter says: “I would say it would be well into next year.”
For further information please email randoxpr@randox.com
Photo Credit Elaine Hill
Want to know more about Randox?
Contact us or visit our homepage to view more.
Our Randox Products and Services
REAGENTS
RX SERIES
ACUSERA
BIOCHIP
Acute Kidney Injury
Acute Kidney Injury
–
Rapid Renal Injury Detection
Multiplex Detection of Acute Kidney Injury from a Single Sample
- Simultaneous and quantitative detection of multiple kidney function markers from a single patient sample for complete patient profiling
- Identify early stage renal impairment and ensure earlier intervention. Widely used in drug-related renal clinical trials
- Unique combination of analytes ensures better sensitivity and accuracy compared to traditional serum creatinine measurement
- The Randox AKI array measures four qualified FDA urine markers from one sample
- Multiplex testing better captures reduced renal function, as each biomarker reflects different mechanisms that result in similar injury outputs
- Utilising patented Biochip Technology, the Randox AKI array is currently available on the Evidence Investigator
Acute kidney injury (AKI) is currently diagnosed using serum creatinine as recommended by the KDIGO guidelines. Serum creatinine however, has poor sensitivity and specificity for AKI lagging behind both renal injury and recovery. There is an immediate need for more sensitive biomarkers to enables earlier identification of AKI, monitor drug toxicity and identify patients at an increased risk of CKD, end-stage renal disease or long-term kidney dialysis.
The National Institute for Health and Care Excellence (NICE) has highlighted that is important that patients are assessed for AKI on admission to hospital or transfer, monitored for AKI throughout their stay and AKI is managed appropriately if it develops.
Utilising patented Biochip Technology, the Randox Acute Kidney Injury (AKI) array simultaneously tests for four novel biomarkers delivering early diagnosis and monitoring of treatment efficacy It may also help you conduct safer and faster clinical trials.
Randox Acute Kidney Injury (AKI) Array (4-plex)
This marker is highly upregulated in kidney tubule cells following nephrotoxic injury severe enough to result in acute renal failure, acute tubular necrosis or acute tubulo-interstitial nephropathy.
Due to its small size and basic pH, Cystatin C is freely filtered by the glomerulus. It is then reabsorbed by tubular epithelial cells and subsequently metabolized. Accumulation of Cystatin C in urine is specific for tubular kidney damage and suggests reduced reabsorption at the proximal tubules as a result of toxicant-induced kidney injury.
Expression of Clusterin is upregulated following a variety of renal injuries and is detectable in urine following acute kidney injury induced by administration of nephrotoxic agents. This occurs before the profound renal transformations that give rise to changes in creatinine and BUN.
KIM-1 is a 30kDa type 1 transmembrane glycoprotein found on actvated CD4+ T cells. It is undetectable in healthy kidney tissue but is expressed at very high levels in proximal tubule epithelial cells in the kidney after toxic injury.
The Evidence Investigator
Meet the Evidence Investigator
The Randox AKI array has been developed for the Evidence Investigator, a semi-automated benchtop immunoassay analyser.
The AKI array would improve patient risk stratification whilst monitoring the effectiveness of treatments & drug toxicity by simultaneously and quantitatively detecting multiple urine biomarkers of kidney damage-related analytes from a single sample.
Want to know more?
Contact us or visit our Investigator Webpage
Chicago’s Rising Fentanyl Problem: A Randox Toxicology Report
Chicago’s Rising Fentanyl Problem: A Randox Toxicology Report
Abuse of opioids, and in particular, fentanyl, has been on the rise in the United States in recent years. The number of patients being prescribed painkillers has almost quadrupled since the 90s from 76 million to 289 million in 2016. It has been described as a uniquely American problem, where pain relief prescriptions are about 40% higher than other developed countries.
Inevitably due to the high addiction rate of opioids, this has unfortunately led to increasing overdose deaths. In 2017 alone over 70,000 people died from drug overdoses in the USA with opioids being involved in 67.8% of cases.
Chicago Illinois is no exception to this crisis. The National Institute of Drug Abuse found that Illinois has a rate of 17.2 deaths per 100,000 people from opioid overdoses, compared to the national average of 14.6. It is not only prescription painkillers that are adding to the opioid addiction crisis in Chicago, but substances such as fentanyl that is illegally sold on the street.
Fentanyl is a cheaper, synthetic opioid which can be 50 times more potent than heroin and 100 times more potent than morphine. It is commonly added to heroin to increase strength and cut costs. Many users believe they are purchasing heroin when in fact it can be mostly fentanyl, resulting in rising overdose deaths. The DEA’s Chicago lab have stated that the drug is making up a more of their workload than ever and becoming a regular drug they see.
Randox Toxicology
Randox Toxicology are world leaders in drug testing solutions with the capability of detecting over 500 drug and drug metabolites using our innovative Biochip Array Technology – the most comprehensive on the drug testing market. Using our revolutionary patented Biochip Array Technology, the Evidence MultiSTAT is a fully automated benchtop analyzer that enables on-site simultaneous detection of up to 21 classical, prescription and synthetic drugs of abuse from a single sample.
Designed to work across a variety of matrices including; whole blood, urine, and oral fluid our patented multi-analyte testing platform provides a complete and highly accurate toxicology profile in 17-20 minutes. Most impressively the MultiSTAT has been designed to be fully operated from sample input to results output by someone with absolutely no laboratory experience and in any environment.
To find out more about our Biochip Array Technology and our Evidence Series range of analysers, visit www.randoxtoxicology.com or email info@randoxtoxicology.com
Randox Toxicology Products and Services
BIOCHIP
EVIDENCE
ELISA
MATRICES
Want to know more about Randox?
Contact us or visit our homepage to view more.
Alcohol consumption during the COVID-19 pandemic
09 July 2020
Alcohol consumption during the COVID-19 pandemic
Alcohol consumption during the COVID-19 pandemic
On 31 December 2019, the Wuhan Municipal Health Commission in Wuhan City, Hubei province, China, reported a cluster of 27 pneumonia cases (including seven severe cases) of unknown aetiology, with a common reported link to Wuhan’s Huanan Seafood Wholesale Market, a wholesale fish and live animal market. On 23 January 2020, Wuhan City was locked down – with all travel in and out of Wuhan prohibited –and movement inside the city was restricted.
By March, the World Health Organisation (WHO) declared COVID-19 a global pandemic, with more than 150 countries worldwide being affected. Many countries, including the UK; imposed stringent public health measures that included the closure of businesses & strict social distancing guidelines.
Due to the enforced lockdown, many within the UK workforce had to make alternative working arrangements, with working from home becoming the new norm. With the closure of businesses and the hospitality sector including bars and restaurants, it meant people seeking alternative means to purchase and consume alcohol.
Before the pandemic, alcohol was attributed to being a financial burden to the UK health system and wider economy. The British Medical Journal estimated that alcohol costs the NHS more than £3.5 billion and the wider economy at least £21bn each year.
The organisation Alcohol Change UK commissioned new research to look at whether people’s drinking habits changed during the COVID-19 lockdown. Over 2,000 people completed the survey, with results weighted to ensure they were representative of the UK population.
The key takeaway from the report is people are consuming alcohol differently because of the lockdown. Around one in five drinkers (21%) told us that they have been drinking more frequently since the lockdown. This suggests that around 8.6 million UK adults are drinking more frequently under lockdown.
Furthermore, while almost half of drinkers said they were drinking about the same amount on a typical drinking day, 15% said they have been drinking more per session since lockdown.
The Global Drug Survey produced a special report for COVID-19 with more than 80,000 participants. The report stated that 44% of those who participated said the frequency of alcohol use increased. Reasons for this included ‘having more time to drink and feeling bored more often.’ However, 25.5% reported having decreased their use of alcohol during COVID-19.
As restrictions begin to ease and more people return to work, it is important to highlight the impact of COVI-19 on the workforce. People’s way of life has changed dramatically, with this change comes different ways of consuming alcohol. It is important to note that the figures above are a proportionate representation based on those who took part, but valuable insights can be gained when looking at alcohol use. For employers who have staff returning to work, their safety is of paramount importance. This will include effectively managing substance misuse, should it be an issue in the workplace.
Effects of Alcohol
Alcohol’s impact on your body starts from the moment you take your first sip. While an occasional glass of wine or beer isn’t a cause for concern, the cumulative effects of drinking wine, beer, or spirits can take its toll.
Consumption of alcohol can impact various parts of the body. Effects can range from weakening of the immune and digestive system, to inflammation and sugar level issues.
Our ‘Effects Of’ Series provides educational posters that can be displayed in workplaces to highlight the dangers of alcohol. Click here for more information.
About Randox Testing Services
Randox Testing Services are a specialist in the workplace drug & alcohol testing sector. We provide a wide range of testing for companies who want to reduce the impact of substance misuse in the workplace. With a range of service options and expert staff on hand to provide help and training, our services will help to eradicate the impact of drugs and alcohol.
Throughout the COVID-19 pandemic, RTS have continued to provide drug & alcohol testing services. At all times, we have ensured our staff are equipped to provide sensible advice and flexible solutions to drug & alcohol testing.
We have provided each Collection Officer with full PPE to ensure they meet requirements for personal and professional safety. Full social distancing guidelines are followed at all times when possible whilst conducting testing. We will continue to advise and navigate companies through this period as more businesses return and testing is required.
If you have any questions regarding drug & alcohol testing, contact us today.
Web: www.randoxtestingservices.com
Email: testingservices@randox.com
Phone: +44 (0) 28 9445 1011
Want to know more?
Contact us or visit our website to read more.
RX modena and Randox Reagents used in COVID-19 hospital in India
RX modena and Randox Reagents used in COVID-19 hospital in India
Randox Laboratories has installed an RX modena into a COVID-19 hospital in India; the Netaji Subhash Chandra Bose Medical College in Madhya Pradesh state.
The installation, which marks the first RX modena to be used in an Indian Government Medical College, replaces existing instrumentation in the Medical College laboratory, an initiative which was driven by College Dean Dr. Pradeep Kumar Kasar and Head of Department Dr. Ashok Kumar Sahu.
The RX modena will cater for an additional 38 samples compared to the previous instrumentation, and is running a range of biochemistry tests that play a pivotal role in COVID-19 patient management, including C-Reactive Protein (CRP), Ferritin, and Lactate Dehydrogenase (LDH).
Dr. Ashok Kumar Sahu, Head of Biochemistry at Netaji Subhash Chandra Bose Medical College, commented;
“We are very pleased with the performance of the RX modena, and in particular with its wide menu of tests that can be utilized for COVID-19 patient management. Its high throughput and versatility have been a great support for the clinicians working in our COVID-19 hospital, in determining risk stratification, disease progression, and response to treatment.”
The RX modena is a high volume, floor standing, fully automated clinical chemistry analyser with a world leading test menu which covers specific proteins, lipids, therapeutic drugs, antioxidants, diabetes and veterinary testing. The versatile analyser offers advanced methodologies with excellent correlation to the gold standard, and excellent reagent CV ranges.
Shail Dholabhai, Randox India Sales Manager, commented;
“We are delighted that the team at Netaji Subhash Chandra Bose Medical College have chosen the RX modena to fulfil the testing requirements of this COVID-19 hospital. Offering an unrivalled test menu of routine and specialized chemistries, the RX modena provides laboratories with the superior precision, reliability and accuracy that the Randox RX series is renowned for.
“Capable of performing a total of 1200 tests per hour including ISE, the RX modena presents a new class of efficiency which will result in faster and more accurate diagnoses, and ultimately, lead to better patient outcomes.”
Benefits of the RX modena
- Capable of performing 800 photometric and a total of 1200 tests per hour including ISE.
- World-leading extensive test menu covering routine chemistries, specific proteins, lipids, antioxidants, cardiac, diabetes and veterinary testing, offering cost savings through consolidation of routine and novel tests on a single platform.
- Economic platform with low water consumption of less than 20 litres per hour saving on consumable costs. The RX modena also requires less than 5 minutes minimal maintenance.
- Interactive touch-screen technology with integrated barcode readers for reagent and sample identification. Increased functionality with 13 wavelengths generated via diffraction grating (340-800nm) ensuring a multitude of chemistries are possible on one system.
- Easy-to-use advanced Microsoft 10 software with a built-in Inventory Management System calculating the number of tests remaining, providing alerts of shortages and expired reagents and calibrators. The RX modena also features automatic test re-run function and sample dilution.
- Dedicated reagent and sample pipettes to minimise the risk of errors and contamination. The RX modena also features a continuous loading hatch to allow for samples to be analysed quickly and easily during a run.
- Advanced QC capabilities with daily, monthly and batch QC with data archiving, Levey-Jennings charts and automatic QC and calibration. There are also 7 different calibration options available.
For further information about the RX modena click here.
For information about laboratory tools for COVID-19 patient management please click here.
For other enquiries please contact marketing@randox.com
Want to know more about Randox?
Contact us or visit our homepage to view more.